Sensus Healthcare, Inc. (SRTS) intrinsic value & 10-year financials

Sensus Healthcare, Inc. (SRTS) has a Graham intrinsic value of $8.04 per share. At $2.77 on Oct 17, 2026, the stock trades 66% below that value. Over the last 10 fiscal years revenue grew 7.1% a year to $27.5M, with an average return on invested capital of 0.5%.

Graham intrinsic value
$8.04
Share price (Oct 17, 2026)
$2.77
Price vs Graham value
66% below
Market cap
$45.2M
Revenue (FY2025)
$27.5M
Revenue growth (10-yr CAGR)
7.1%
ROIC (10-yr avg)
0.5%
Free cash flow (FY2025)
$332.0K

SRTS 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $27.5M -$7.7M -$0.47 $332.0K -37.5% -27.4%
FY2024 $41.8M $6.6M $0.41 -$1.1M 19.4% 19.7%
FY2023 $24.4M $485.0K $0.03 -$2.4M -1.6% -1.1%
FY2022 $44.5M $24.2M $1.46 -$1.6M 33.3% 54.9%
FY2021 $27.0M $4.1M $0.25 -$414.0K 15.2% 55.7%
FY2020 $9.6M -$6.8M -$0.42 -$792.7K -86.0% -48.1%
FY2019 $27.3M -$1.7M — -$2.5M -7.2% -8.1%
FY2018 $26.4M -$2.0M — -$9.4M -7.6% -10.6%
FY2017 $20.6M -$3.7M — -$3.3M -18.1% -27.5%
FY2016 $14.8M -$346.4K — -$1.1M -2.5% -2.3%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

Sensus Healthcare, Inc. has demonstrated mature, steady growth, with revenue compounding at 7.1% annually over the past decade.

Sensus Healthcare, Inc. has historically struggled to out-earn its cost of capital, averaging just 0.5% ROIC.

Sensus Healthcare, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, Sensus Healthcare, Inc. is modeled at 7.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $8.04 per share.

SRTS stock: frequently asked questions

What is the intrinsic value of Sensus Healthcare, Inc. (SRTS) stock?

Using Benjamin Graham's revised formula, V = EPS × (8.5 + 2g) × 4.4 / Y, with reported diluted earnings per share, a 7.1% normalized growth rate (capped at 15%) and a 5.1% AAA corporate bond yield, SRTS's intrinsic value is about $8.04 per share.

Is SRTS stock undervalued?

At $2.77 (close on Oct 17, 2026), SRTS trades 66% below its Graham value of $8.04. On Graham's terms that leaves a margin of safety. A formula is a starting point for research, not a recommendation.

How fast has Sensus Healthcare, Inc. grown?

Revenue went from $14.8M in fiscal 2016 to $27.5M in fiscal 2025, a compound annual growth rate of 7.1%. Net income was -$7.7M in fiscal 2025.

Does Sensus Healthcare, Inc. generate free cash flow?

Sensus Healthcare, Inc. generated $332.0K of free cash flow (operating cash flow minus capital expenditures) in fiscal 2025. Free cash flow was positive in 1 of the last 10 reported years.

What is SRTS's return on invested capital?

Average ROIC over the last 10 fiscal years was 0.5%, and average return on equity was 0.7%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this SRTS data come from?

From Sensus Healthcare, Inc.'s annual 10-K filings on SEC EDGAR, most recently filed May 13, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar surgical & medical instruments & apparatus stocks